Navigation Links
Michael J. Fox Foundation grant to Dr. Samuel Young will provide Parkinson's drug development tools
Date:5/3/2012

Samuel M. Young, Jr., PhD, research group leader at the new Max Planck Florida Institute (MPFI), has received his first grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). The grant will enable Dr. Young and colleagues to develop a technology that will help scientists working in drug development to research potential treatments that target LRRK2, a Parkinson's-related gene. Globally, five million people have Parkinson's disease.

"We are excited about receiving The Michael J. Fox Foundation grant, as these grants are competitive and MJFF is the world's largest private funder of Parkinson's research," said Dr. Young, who directs MPFI's Molecular Mechanisms of Synaptic Function research group. "We believe that the tools we develop will prove important in advancing Parkinson's research."

Translational researchers working in Parkinson's disease have been hindered in studying the function of the LRRK2 gene in pre-clinical models of Parkinson's. This has been due to difficulty in expressing this gene with commonly used neuroscience research tools known as recombinant viral vectors. Dr. Young will develop tools that will allow researchers to get around this problem.

Mutations in the gene for leucine-rich repeat kinase 2 (LRRK2) are among the most common genetic links to Parkinson's disease yet discovered. LRRK2 has garnered much excitement among drug makers due to its reported protein kinase activity, which appears to be enhanced by Parkinson's disease-causing mutations.

"We are delighted that The Michael J. Fox Foundation has awarded Dr. Young with a grant to lead this critical project," said David Fitzpatrick, PhD, CEO and Scientific Director of MPFI. "This grant recognizes Dr. Young's specialized expertise, as well as our Institute's leadership role in neural circuit research."

Recombinant viral vectors are used by scientists to deliver genetic material into cells. Viruses have evolved specialized molecular mechanisms to efficiently transport their genomes inside the cells they infect. To create the vector, viruses are bioengineered to strip their viral genome or most of their viral genome, which renders them harmless. This enables them to carry transgene expression cassettes to express a gene of interest. The transgene expression cassette is a fragment of DNA that carries the regulatory elements necessary for cells to express specific genes within a cell or organism.

As the principal investigator of the project, Dr. Young will work with collaborators at other institutions to generate the optimal expression cassette to express LRRK2.

Dr. Young has specialized training that makes him the ideal investigator for this project. After training in virology and in recombinant viral vectors during his doctoral studies, Dr. Young switched fields and became a post-doctoral neuroscience researcher, learning electrophysiology techniques. He carried out a second post-doctoral position, gaining further experience with advanced electrophysiological techniques as well as calcium imaging. Using this unique training, which combines techniques in molecular, electrophysiological and biophysical methods, Dr. Young and his group at MPFI study the molecular mechanisms regulating synaptic function. Understanding these mechanisms is critical because the major causes of brain diseases are due to synaptic dysfunction.

Since Dr. Young's arrival at MPFI in 2010, he and his team have made significant progress in their research. After finding that most transgene expression cassettes were not optimized for high level expression for use in neuroscience research, the team, including Dr. Monica Montesinos and graduate student Zuxin Chen, developed and published a research manuscript describing a novel expression cassette known as "pUNISHER" for neuroscience applications. The cassette, which can be used inside a living organism (in vivo) or in cell culture (in vitro), has the potential to help the research of scientists studying the molecular mechanisms of brain function, and to ultimately be used in translational research on disorders such as Parkinson's, Huntington's and Alzheimer's diseases.


'/>"/>

Contact: Dennis Tartaglia
dtartaglia@tartagliacommunications.com
732-545-1848
Tartaglia Communications
Source:Eurekalert

Related biology news :

1. AnaptysBio Adds Dr. David L. Lacey and Dr. Michael Gallatin to Therapeutic Advisory Board
2. St. Michaels and King Saud University receive first joint patent
3. New findings by St. Michaels researchers about the way cells work
4. The Michael J. Fox Foundation awards nearly $200,000 to develop novel drugs for Parkinsons disease
5. LLNL selects Madhav Marathe for the first George A. Michael Distinguished Scholar Award
6. Dr. Michael Collins publishes paper on ivory-billed woodpecker
7. Michael S. Watson, Ph.D., receives Am College of Medical Genetics-ACMG Foundation Presidents Award
8. 2011 HFSP Nakasone Award for Michael Elowitz of Caltech
9. Michael Graetzel wins the Millennium Technology Prize
10. Adult Star Katie Michaels Attending NHL Game 7 Red Wings vs. Coyotes
11. Michael Betenbaugh wins 2010 Cell Culture Engineering award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
Breaking Biology Technology: